6.43
-1.68%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bolt Biotherapeutics
From its filings with the US Securities and Exchange Commission
Bolt Biotherapeutics is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BOLT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $7.7m and a net loss of $33.4m. At that date it held total assets of $56.7m and shareholders' equity of $26.5m.
BDC-4182 is a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2. Claudin 18.2 is a clinically validated target in oncology with zolbetuximab, a claudin 18.2-targeted monoclonal antibody, approved in Japan, the U.S., and other countries for the treatment of patients with claudin 18.2-positive, unresectable, advanced or recurrent gastric cancer in combination with chemotherapy. Other programs targeting claudin 18.2 are in development for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. BDC-4182 is supported by in vitro and in vivo experiments demonstrating potent anti-tumor activity in multiple preclinical models, safety and tolerability in toxicology studies, and enhanced anti-tumor activity compared to cytotoxic antibody-drug conjugates, or ADCs, in murine tumor models. Data on our claudin 18.2 Boltbody ISAC program was presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meetings in November 2025, 2024 and 2023. The first-in-human Phase 1 dose escalation trial of BDC-4182 is ongoing in subjects with gastric/gastroesophageal junction cancer.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Feb 2021
- Employees
- 94
- Website
- boltbio.com ↗
- Head office
- 900 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. William QuinnPresident, Chief Executive Officer, Chief Financial Officer, Director, since 2020$1.2m
- Mr. Grant YonehiroChief Operating Officer$948,414
- Dr. Laura BernerIndependent Director$54,902
- Dr. Jakob DupontIndependent Director$47,727
- Ms. Kathleen LaporteIndependent Director$65,902
- Mr. Brian O'CallaghanIndependent Director$75,652
- Dr. Nicole OnettoIndependent Director$60,402
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bolt Biotherapeutics' proprietary Boltbody ISAC platform targets HER2 with BDC-1001 in Phase II trials.
- BDC-3042 program repolarizes tumor-associated macrophages via Dectin-2 agonist antibodies.
- Clinical-stage biopharmaceutical company with 94 employees focused on cancer immunotherapies.
Weaknesses
- Bolt Biotherapeutics has only two clinical programs BDC-1001 and BDC-3042 in development.
- The company's IPO occurred in February 2021 with limited financial history.
- Redwood City headquarters may limit access to broader biotech talent pools.
Opportunities
- Expanding Phase II trials for BDC-1001 in HER2-positive cancer treatments.
- Dectin-2 agonist program BDC-3042 could target multiple tumor microenvironment pathways.
- Growing demand for innovative cancer immunotherapies in the Health Care sector.
Threats
- Competition from established biotech firms in the Health Care sector.
- Regulatory hurdles for novel immunotherapy platforms like Boltbody ISAC.
- Potential delays in Phase II clinical trials for BDC-1001 and BDC-3042.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.